加载中
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
前收盘价
US$5.85
−US$0.80 · -12.03%
盘后
US$6.43
+US$0.58 · +9.91%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
日内区间
当前US$5.85
52周区间
当前US$5.85
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
28
偏贵
情绪
52
多空交织
风险
82
极高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
日内区间
当前US$5.85
52周区间
当前US$5.85
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 203.67万 USD | 214万 USD | 208.53万 USD | 207.96万 USD | 142.22万 USD |
| 销货成本 | 147.03万 USD | 144万 USD | 122.32万 USD | 132.92万 USD | 91.78万 USD |
| 毛利 | 56.63万 USD | 69.93万 USD | 86.21万 USD | 75.04万 USD | 50.43万 USD |
| 研究与开发 | 189.11万 USD | 311.9万 USD | 196.04万 USD | 98.22万 USD | 41.14万 USD |
| 销售、一般及管理费用 | 699.31万 USD | 427万 USD | 377.36万 USD | 391.6万 USD | 402.28万 USD |
| 营业费用 | 888.43万 USD | 738.9万 USD | 573.4万 USD | 489.83万 USD | 443.42万 USD |
| 利息收入 | — | 19.17万 USD | 1.69万 USD | — | — |
| 利息支出 | 2.25万 USD | 2.14万 USD | 7.58万 USD | 8289 USD | 11.84万 USD |
| 折旧和摊销 | 19.38万 USD | 28.51万 USD | 28.77万 USD | 36.9万 USD | 31.83万 USD |
| 营业利润 | −831.8万 USD | −669万 USD | −487.19万 USD | −414.79万 USD | −392.99万 USD |
| 净利润 | −822.96万 USD | −1048.3万 USD | −548.53万 USD | −481.08万 USD | −842.24万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年8月12日 | 583:500 | — | — |
股票拆分 | 2019年7月24日 | 1:4 | — | — |
已生效 2022年8月12日
583:500
已生效 2019年7月24日
1:4
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
